ASCO 2023: Breast cancer research highlights
ASCO 2023: Breast cancer research highlights
Ciltacabtagene autoleucel greatly reduces risk of disease progression in lenalidomide-refractory MM
mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity
ASCO 2023: Head and neck highlights
Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to cabozantinib alone in soft tissue sarcoma
Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment
Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma
Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients
Optimising cervical cancer care in Nigeria
Choosing cancer medicines wisely in Africa
Olaparib plus ceralasertib might benefit paediatric cancer patients with DNA repair-deficient tumours
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?